Pluri Biotech has secured a patent from the China National Intellectual Property Administration (CNIPA) for its proprietary 3D immune cell expansion and activation technology. This milestone integrates China into Pluri’s existing global IP network, which already covers the United States, Japan, South Korea, Australia, and Israel.
The technical foundation of Pluri’s platform includes:
- Biomimetic Environment: A unique bioreactor system designed to mimic the human lymph node environment to enhance cell growth.
- Massive Scalability: An automated manufacturing platform capable of expanding billions of immune cells, ensuring cost-efficiency and high-quality standards.\
- Broad Therapeutic Scope: The technology supports various cell types, including conventional T cells, CAR-T therapies, Natural Killer (NK) cells, and tumor-infiltrating lymphocytes.
By securing protection in China, a leading market for chimeric antigen receptor T cell (CAR-T) innovation, Pluri reinforces its strategy to provide a globally protected CDMO (Contract Development and Manufacturing Organization) platform. The company aims to facilitate large-scale production for international partners across regenerative medicine and oncology.